| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sassa K et al. | Therapeutic effect of clarithromycin on a transplanted tumor in rats. | 1999 | Antimicrob. Agents Chemother. | pmid:9869567 |
| van Westrhenen R et al. | Pneumonia and glomerulonephritis caused by Mycoplasma pneumoniae. | 1998 | Nephrol. Dial. Transplant. | pmid:9870493 |
| Waddell ST et al. | Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9871759 |
| Lee CL et al. | One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. | 1998 | J. Formos. Med. Assoc. | pmid:9872028 |
| Suzuki J et al. | Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. | 1998 | J. Clin. Gastroenterol. | pmid:9872515 |
| Sakaki N et al. | Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. | 1998 | J. Clin. Gastroenterol. | pmid:9872520 |
| Yoshida Y et al. | Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9873455 |
| Sakurai N et al. | Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. | 1998 | Bioorg. Med. Chem. Lett. | pmid:9873510 |
| Komori T et al. | Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. | 1998 | Res. Commun. Mol. Pathol. Pharmacol. | pmid:9874281 |
| Matteelli A et al. | Long term treatment with clarithromycin for cryptosporidiosis and emergence of drug resistant disseminated infection due to Mycobacterium avium: case report. | 1998 | J Chemother | pmid:9876056 |
| Vorbach H et al. | Endothelial cell compatibility of clarithromycin for intravenous use. | 1998 | Clin. Biochem. | pmid:9876898 |
| Sakamoto M et al. | [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer]. | 1998 | Gan To Kagaku Ryoho | pmid:9881083 |
| Komori T et al. | Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. | 1998 | Biol. Pharm. Bull. | pmid:9881659 |
| MartÃn Mir ML et al. | [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule]. | 1998 | Gastroenterol Hepatol | pmid:9882932 |
| Tohnai A et al. | Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. | 1998 Nov-Dec | Am J Rhinol | pmid:9883303 |
| Gisbert JP et al. | [Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?]. | 1998 | Med Clin (Barc) | pmid:9887438 |
| Baena DÃez JM et al. | [Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care]. | 1998 | Aten Primaria | pmid:9887574 |
| Williams SL et al. | Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis. | 1999 | J. Clin. Microbiol. | pmid:9889208 |
| Lygren I et al. | [Treatment of Helicobacter pylori infection]. | 1998 | Tidsskr. Nor. Laegeforen. | pmid:9889634 |
| Einarson A et al. | A prospective controlled multicentre study of clarithromycin in pregnancy. | 1998 | Am J Perinatol | pmid:9890248 |
| Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
| Abe M et al. | A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. | 1998 | Respir Med | pmid:9893782 |
| Lacy MK et al. | Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. | 1998 | Int. J. Antimicrob. Agents | pmid:9916901 |
| Fera MT et al. | Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method. | 1998 | Int. J. Antimicrob. Agents | pmid:9916902 |
| Miglioli PA et al. | Antibacterial activity of human pleural fluid: alone and in combination with antibiotics. | 1998 | Int. J. Antimicrob. Agents | pmid:9916908 |
| Garrido A et al. | [Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity]. | 1998 | Enferm. Infecc. Microbiol. Clin. | pmid:9918994 |
| Lind T et al. | The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. | 1999 | Gastroenterology | pmid:9922303 |
| Kuipers EJ and Klinkenberg-Knol EC | Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. | 1999 | Gastroenterology | pmid:9922329 |
| Matsushima T and Miyashita N | [Basic and clinical study of Chlamydia pneumoniae infections]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9922675 |
| Stefansson P et al. | Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. | 1998 | Rhinology | pmid:9923060 |
| GarcÃa-Arata MI et al. | Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. | 1999 | Antimicrob. Agents Chemother. | pmid:9925537 |
| Lindeboom JA et al. | Clarithromycin as a single-modality treatment in mycobacterial avium-intracellular infections. | 1999 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:9927080 |
| Principi N and Esposito S | Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. | 1999 | Drug Saf | pmid:9935275 |
| Desta Z et al. | Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). | 1999 | Clin. Pharmacol. Ther. | pmid:9951426 |
| Yonemochi E et al. | Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. | 1999 | Eur J Pharm Sci | pmid:9971917 |
| Piquette RK | Torsade de pointes induced by cisapride/clarithromycin interaction. | 1999 | Ann Pharmacother | pmid:9972380 |